141 related articles for article (PubMed ID: 8324869)
1. Disposition of total and unbound etoposide following high-dose therapy.
Schwinghammer TL; Fleming RA; Rosenfeld CS; Przepiorka D; Shadduck RK; Bloom EJ; Stewart CF
Cancer Chemother Pharmacol; 1993; 32(4):273-8. PubMed ID: 8324869
[TBL] [Abstract][Full Text] [Related]
2. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
Stewart CF; Arbuck SG; Fleming RA; Evans WE
J Clin Oncol; 1990 Nov; 8(11):1874-9. PubMed ID: 2230875
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
5. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.
Stewart CF; Fleming RA; Arbuck SG; Evans WE
Cancer Res; 1990 Nov; 50(21):6854-6. PubMed ID: 2208152
[TBL] [Abstract][Full Text] [Related]
7. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation.
Rodman JH; Murry DJ; Madden T; Santana VM
J Clin Oncol; 1994 Nov; 12(11):2390-7. PubMed ID: 7964955
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of high-dose etoposide after short-term infusion.
Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H
Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079
[TBL] [Abstract][Full Text] [Related]
9. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
10. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens.
Würthwein G; Klingebiel T; Krümpelmann S; Metz M; Schwenker K; Kranz K; Lanvers C; Boos J
Anticancer Drugs; 2002 Jan; 13(1):101-10. PubMed ID: 11914647
[TBL] [Abstract][Full Text] [Related]
12. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
[TBL] [Abstract][Full Text] [Related]
15. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
16. Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
van Tellingen O; Kuck MT; Vlasveld LT; Rodenhuis S; Nooijen WJ; Beijnen JH
Cancer Chemother Pharmacol; 1996; 38(4):387-90. PubMed ID: 8674164
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
[TBL] [Abstract][Full Text] [Related]
18. Etoposide pharmacokinetics in patients with normal and abnormal organ function.
Arbuck SG; Douglass HO; Crom WR; Goodwin P; Silk Y; Cooper C; Evans WE
J Clin Oncol; 1986 Nov; 4(11):1690-5. PubMed ID: 3772420
[TBL] [Abstract][Full Text] [Related]
19. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
[TBL] [Abstract][Full Text] [Related]
20. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]